Effect of N-Acetylcysteine (NAC) on Creatinine in Chronic Kidney Disease

Lawson Health Research Institute

Status and phase: Completed; Phase 3

Conditions: Chronic Kidney Disease

Treatments: Drug: N-acetylcysteine; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT00506506

R-07-358

13514

Details and patient eligibility

About

N-acetylcysteine is used to reduce the risk of injury to the kidney after the administration of contrast dye. The mechanism and effectiveness of this intervention is not substantiated in the literature. The investigators hypothesize that serum creatinine will be lower in patients who receive NAC compared to those who receive the placebo but serum cystatin C will not change in patients who receive NAC compared to those who receive the placebo. Also urine creatinine will increase after the administration of NAC compared to before the administration of NAC.

Enrollment: 60 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

1. Patients with an eGFR between 30-60 ml/min calculated using last available creatinine and patient weight.
2. Age > 18
3. No known allergies to or adverse effects from NAC
4. No known scheduled radio-contrast procedures
5. No medications known to affect creatinine secretion

Trial design

60 participants in 2 patient groups, including a placebo group

1

Experimental group

Description:

N-acetylcysteine 1200 mg twice daily x 48 hours

Treatment:

Drug: N-acetylcysteine

2

Placebo Comparator group

Treatment:

Drug: Placebo